AR072871A1 - Combinacion terapeutica que comprende un inhibidor de aurora quinasa y un agente antineoplasico, composicion farmaceutica - Google Patents
Combinacion terapeutica que comprende un inhibidor de aurora quinasa y un agente antineoplasico, composicion farmaceuticaInfo
- Publication number
- AR072871A1 AR072871A1 ARP090102681A ARP090102681A AR072871A1 AR 072871 A1 AR072871 A1 AR 072871A1 AR P090102681 A ARP090102681 A AR P090102681A AR P090102681 A ARP090102681 A AR P090102681A AR 072871 A1 AR072871 A1 AR 072871A1
- Authority
- AR
- Argentina
- Prior art keywords
- antineoplastic
- agents
- pharmaceutical composition
- combination
- therapeutic combination
- Prior art date
Links
- 230000000118 anti-neoplastic effect Effects 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 3
- 239000002246 antineoplastic agent Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 abstract 2
- 229940044684 anti-microtubule agent Drugs 0.000 abstract 2
- 239000002256 antimetabolite Substances 0.000 abstract 2
- 229940125904 compound 1 Drugs 0.000 abstract 2
- 150000003057 platinum Chemical class 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicacion 1: Una combinacion terapéutica caracterizada porque comprende (a) el compuesto 1 de formula (1), y (b) uno o más agentes antineoplásicos seleccionados del grupo consistente en derivados de platino, agentes antimetabolitos, inhibidores de topoisomerasa 1 y agentes antimicrotubulos, donde los ingredientes activos de la combinacion están presentes en cada caso en forma libre o en la forma de una sal farmacéuticamente aceptable o cualquier hidrato de los mismos. Reivindicacion 11: Un método para tratar o retardar el avance de un trastorno proliferativo, caracterizado porque comprende una administracion simultánea, secuencial o separada a un paciente que la necesita, de una cantidad terapéuticamente eficaz de la combinacion de acuerdo con cualquiera de las reivindicaciones 1 a la 9. Reivindicacion 12: Una composicion farmacéutica caracterizada porque comprende una combinacion de acuerdo con cualquiera de las reivindicaciones 1 a la 9, mezclada con un vehículo, diluyente o excipiente farmacéuticamente aceptable. Reivindicacion 14: Un método para disminuir los efectos secundarios causados por la terapia antineoplásica con un agente antineoplásico en mamíferos, incluyendo humanos, que lo necesitan, el método caracterizado porque comprende administrar a dicho mamífero una preparacion combinada que comprende el compuesto 1 de formula (1) de acuerdo con la reivindicacion 1 y uno o más agentes antineoplásicos seleccionados del grupo que consiste en derivados de platino, agentes antimetabolitos, inhibidores de topoisomerasa 1 y agentes antimicrotubulos, en cantidades eficaces para producir un efecto antineoplásico sinérgico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8323208P | 2008-07-24 | 2008-07-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072871A1 true AR072871A1 (es) | 2010-09-29 |
Family
ID=41092158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102681A AR072871A1 (es) | 2008-07-24 | 2009-07-15 | Combinacion terapeutica que comprende un inhibidor de aurora quinasa y un agente antineoplasico, composicion farmaceutica |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20110117212A1 (es) |
| EP (1) | EP2344156B1 (es) |
| JP (1) | JP5518062B2 (es) |
| CN (1) | CN102105147B (es) |
| AR (1) | AR072871A1 (es) |
| ES (1) | ES2703739T3 (es) |
| TW (1) | TW201008944A (es) |
| WO (1) | WO2010009967A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS61047B1 (sr) * | 2015-03-04 | 2020-12-31 | Univ Texas | Postupci za lečenje kancera sa hemizigotnim gubitkom gena tp53 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7141568B2 (en) * | 2003-07-09 | 2006-11-28 | Pfizer Italia S.R.L. | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| EP2026805A1 (en) * | 2006-05-08 | 2009-02-25 | Astex Therapeutics Limited | Pharmaceutical combinations of diazole derivatives for cancer treatment |
| WO2007136615A2 (en) * | 2006-05-16 | 2007-11-29 | Merck & Co., Inc. | Combination cancer therapy |
| EP2117539B1 (en) * | 2006-11-03 | 2010-09-01 | Nerviano Medical Sciences S.r.l. | A method of administering an antitumor compound |
| EP2079746A2 (en) * | 2006-11-08 | 2009-07-22 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
| WO2008135232A1 (en) * | 2007-05-02 | 2008-11-13 | Riccardo Cortese | Use and compositions of purine derivatives for the treatment of proliferative disorders |
| US20100216828A1 (en) * | 2007-08-16 | 2010-08-26 | Christine Dierks | Methods and compositions for treating cancers |
| WO2009091476A1 (en) * | 2008-01-14 | 2009-07-23 | Irm Llc | Compositions and methods for treating cancers |
-
2009
- 2009-07-03 WO PCT/EP2009/058413 patent/WO2010009967A1/en not_active Ceased
- 2009-07-03 EP EP09780134.4A patent/EP2344156B1/en not_active Not-in-force
- 2009-07-03 US US13/054,646 patent/US20110117212A1/en not_active Abandoned
- 2009-07-03 ES ES09780134T patent/ES2703739T3/es active Active
- 2009-07-03 JP JP2011519103A patent/JP5518062B2/ja not_active Expired - Fee Related
- 2009-07-03 CN CN2009801286427A patent/CN102105147B/zh not_active Expired - Fee Related
- 2009-07-15 AR ARP090102681A patent/AR072871A1/es unknown
- 2009-07-23 TW TW098124835A patent/TW201008944A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102105147B (zh) | 2013-07-03 |
| JP2011528680A (ja) | 2011-11-24 |
| TW201008944A (en) | 2010-03-01 |
| JP5518062B2 (ja) | 2014-06-11 |
| EP2344156A1 (en) | 2011-07-20 |
| WO2010009967A1 (en) | 2010-01-28 |
| US20110117212A1 (en) | 2011-05-19 |
| HK1154344A1 (en) | 2012-04-20 |
| ES2703739T3 (es) | 2019-03-12 |
| CN102105147A (zh) | 2011-06-22 |
| EP2344156B1 (en) | 2018-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR048502A1 (es) | Sinergia terapeutica de compuestos anti-cancer | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| AR090349A1 (es) | Terapia de combinacion para trastornos proliferativos, kit y uso | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| UY26635A1 (es) | Métodos sinérgicos y composiciones para el tratamiento del cáncer | |
| WO2015095819A3 (en) | Cancer treatment using combinations of erk and raf inhibitors | |
| AR067495A1 (es) | Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco | |
| AR085662A1 (es) | Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia | |
| ECSP109935A (es) | Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k | |
| BRPI0508461B8 (pt) | diaminopirimidinas, seus usos, e composição farmacêutica | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| CO6280574A2 (es) | Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia | |
| AR107828A1 (es) | 2-amino-n-[7-metoxi-2,3-dihidroimidazo-[1,2-c]quinazolin-5-il]pirimidin-5-carboxamidas como inhibidor de pi3k | |
| ECSP17000643A (es) | Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol. | |
| AR076784A1 (es) | Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasico | |
| ECSP13012538A (es) | Combinaciones que contienen n-(2-arilamino)arilsulfonamida sustituida | |
| CO6260085A2 (es) | Composicion farmaceutica que contiene una combinacion sinergica de venotonicos y vasoprotectores | |
| AR040792A1 (es) | Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas | |
| UY31417A1 (es) | Una composicion farmacéutica y un proceso para dicha composicion farmacéutica | |
| RU2008148597A (ru) | Фармацевтические комбинации | |
| AR064543A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| BR112015012497A8 (pt) | combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial | |
| WO2015035410A8 (en) | Cancer therapy | |
| UY31826A (es) | Compuesto peptídico y su uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |